Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Jade Biosciences, Inc.
NASDAQ:JBIOHealthcare · Biotechnology
-1.26%$14.06
AH$14.06+0.00%vs close
Mkt Cap$894.18M
Float54.08M
O/S63.6M
Vol
$ Vol
RVOL
Inst Own-
SI20.7%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$127.41M
Total Assets$349.78M
Free Cash Flow-$94.89M
Debt & Equity
Debt 0%
Equity 100%
Preferred 0%
Total Debt$724K
Total Equity$332.52M
Preferred Stock$2K
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in JBIO's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$349.78M
Liabilities$17.26M
Accounts Receivable$0
Accounts Payable$2.15M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $0 | $282K | $96K | $68K | $15K | $1K |
| Gross Profit | $0 | -$282K | -$96K | -$68K | -$15K | -$1K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $93.12M | $53.19M | $64.22M | $38.62M | $14.99M | $7.94M |
| Selling, General, and Administrative | $20.42M | $21.13M | $17.09M | $14.55M | $8.02M | $948K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $113.54M | $74.31M | $81.31M | $53.17M | $23.01M | $8.89M |
| Operating Income (EBIT) | -$113.54M | -$74.6M | -$81.41M | -$53.24M | -$23.02M | -$8.89M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $75K |
| Interest Income | $7.78M | $5.04M | $5.95M | $1.83M | $65K | $0 |
| Other Income (Expense) | -$13.81M | $5.02M | $5.94M | $1.75M | $62K | -$722K |
| Income Before Tax (EBT) | -$127.35M | -$69.57M | -$75.47M | -$51.49M | -$22.96M | -$9.61M |
| Income Tax Expense | $58K | $55K | $56K | $25K | $3K | $0 |
| Net Income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M | -$9.61M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -4.06 | -85.26 | -100.38 | -73.67 | -32.96 | -14.00 |
| Diluted EPS | -4.06 | -85.26 | -100.38 | -73.67 | -32.96 | -14.00 |
| Weighted Average OS | 31.36M | 816,634 | 752,332 | 699,202 | 697,439 | 697,439 |
| EBITDA | -$127.33M | -$69.29M | -$75.37M | -$51.42M | -$22.95M | -$9.54M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $88.44M | $33.75M | $23.49M | $22.4M | $54.2M | $4.57M |
| Short-Term Investments | $247.72M | $44.87M | $98.95M | $106.82M | $113.18M | $0 |
| Cash and Short-Term Investments | $336.16M | $78.62M | $122.44M | $129.22M | $167.38M | $4.57M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $845K | $250K | $295K | $240K | $103K |
| Total Current Assets | $336.16M | $80.12M | $124.23M | $131.5M | $174.33M | $4.68M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $0 | $215K | $902K | $1.25M | $728K | $39K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $13.62M | $0 | $2.28M | $2.56M | $302K | $0 |
| Total Long-Term Assets | $13.62M | $215K | $3.19M | $3.8M | $1.03M | $39K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $349.78M | $80.33M | $127.42M | $135.3M | $175.36M | $4.71M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $2.15M | $224K | $2.4M | $2.58M | $1.21M | $618K |
| Short-Term Debt | $0 | $417K | $420K | $385K | $192K | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $3.32M | $319K | $10.45M | $3.13M | $360K | $964K |
| Total Current Liabilities | $16.54M | $3.83M | $17.64M | $7.78M | $2.55M | $1.77M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $70K | $70K | $71K | $13K | $0 |
| Total Long-Term Liabilities | $724K | $70K | $325K | $776K | $395K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $17.26M | $3.9M | $17.96M | $8.56M | $2.94M | $1.77M |
| Stockholders' Equity | ||||||
| Preferred Stock | $2K | $0 | $0 | $0 | $0 | $16.29M |
| Common Stock | $5K | $3K | $3K | $2K | $2K | $0 |
| Retained Earnings | -$174.39M | -$233.05M | -$163.42M | -$87.9M | -$36.39M | -$13.41M |
| Comprehensive Income & Other | $129K | $105K | $237K | -$466K | -$59K | $0 |
| Other Stockholders' Equity | $506.9M | $309.48M | $272.88M | $214.64M | $208.81M | $16.35M |
| Total Equity | $332.52M | $76.43M | $109.46M | $126.74M | $172.42M | $2.94M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $349.78M | $80.33M | $127.42M | $135.3M | $175.36M | $4.71M |
| Supplementary Data | ||||||
| Total Debt | $724K | $417K | $675K | $1.09M | $574K | $0 |
| Net Debt | -$87.71M | -$33.33M | -$22.82M | -$21.31M | -$53.62M | -$4.57M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M | -$9.61M |
| Depreciation & Amortization | $26K | $282K | $96K | $68K | $15K | $1K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $20.01M | $0 | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $361K | -$2.17M | -$164K | $1.37M | $609K | $37K |
| Other Working Capital | -$8.56M | -$9M | $9.96M | $6.39M | -$7.12M | $937K |
| Total Working Capital Change | -$8.2M | -$11.17M | $9.8M | $7.75M | -$6.51M | $974K |
| Other Non-Cash Items | $20.88M | $9.32M | $8.85M | $4.57M | $2.06M | $777K |
| Net Cash from Operating | -$94.69M | -$71.2M | -$56.78M | -$39.12M | -$27.4M | -$7.86M |
| Investing Activities | ||||||
| Capital Expenditures | -$196K | $0 | -$142K | -$195K | -$181K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$261.19M | -$19.68M | -$123.98M | -$147.62M | -$113.25M | $0 |
| Sales of Investments | $14.41M | $75.71M | $136M | $154.74M | $0 | $0 |
| Other Investing Activities | -$31K | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$247.01M | $56.03M | $11.88M | $6.93M | -$113.43M | $0 |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | -$2.5M |
| Common Stock Issuance | $189.5M | $25.43M | $46M | $396K | $190.46M | $6.42M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $171.27M | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing | $360.77M | $25.43M | $46M | $396K | $190.46M | $8.92M |
| Forex Effect | -$21K | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $19.05M | $10.26M | $1.09M | -$31.8M | $49.62M | $1.06M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$94.69M | -$71.2M | -$56.78M | -$39.12M | -$27.4M | -$7.86M |
| Capital Expenditure | -$196K | $0 | -$142K | -$195K | -$181K | $0 |
| Free Cash Flow | -$94.89M | -$71.2M | -$56.92M | -$39.32M | -$27.58M | -$7.86M |
| Cash at Beginning | $69.39M | $23.49M | $22.4M | $54.2M | $4.57M | $3.51M |
| Cash at End | $88.44M | $33.75M | $23.49M | $22.4M | $54.2M | $4.57M |